- Mucopolysaccharidosis (MPS), a group of rare lysosomal storage disorders caused by the absence or malfunctioning of specific enzymes, is gaining increasing attention due to advancements in diagnostics and therapeutic interventions, particularly in enzyme replacement therapies and gene-based approaches
- The escalating demand for effective MPS treatments is primarily fueled by increasing awareness among healthcare providers, enhanced newborn screening programs, and supportive government initiatives for orphan drug development
- North America dominated the mucopolysaccharidosis market with the largest revenue share of 39.2% in 2024, supported by well-established healthcare infrastructure, significant R&D investments, and favorable regulatory pathways, with the U.S. at the forefront owing to its proactive rare disease research ecosystem and availability of FDA-approved therapies
- Asia-Pacific is expected to be the fastest growing region in the mucopolysaccharidosis market during the forecast period due to expanding healthcare access, growing awareness, and rising investments in rare disease diagnostics and treatment
- The Mucopolysaccharidosis Type I, segment dominated the mucopolysaccharidosis market with a market share of 35% in 2024, driven by early disease identification, availability of specific enzyme replacement therapies, and focused clinical research on improving long-term patient outcomes
